Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.38 |
| ▸ | GYS1 | P13807 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834850 | 0.95 | L3MBTL1 (0.44) | ACEACE2L3MBTL1TSHRGYS1 | |
| SCHEMBL17834603 | 0.94 | L3MBTL1 (0.44) | ACEACE2L3MBTL1TSHRGYS1 | |
| SCHEMBL15037156 | 0.90 | L3MBTL1 (0.44) | ACEACE2L3MBTL1TSHR | |
| SCHEMBL16295171 | 0.90 | L3MBTL1 (0.44) | ACEACE2L3MBTL1TSHR | |
| SCHEMBL19465510 | 0.90 | L3MBTL1 (0.44) | ACEACE2L3MBTL1TSHR | |
| SCHEMBL16342948 | 0.90 | L3MBTL1 (0.44) | ACEACE2L3MBTL1TSHR | |
| SCHEMBL15037148 | 0.90 | L3MBTL1 (0.44) | ACEACE2L3MBTL1TSHR | |
| SCHEMBL17834829 | 0.90 | L3MBTL1 (0.49) | ACEACE2L3MBTL1TSHRNPSR1 | |
| SCHEMBL16380213 | 0.88 | L3MBTL1 (0.42) | ACEACE2L3MBTL1TSHR | |
| SCHEMBL19485609 | 0.87 | S1PR5 (0.38) | L3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ACE 3137/4885ACE2 3162/4885L3MBTL1 771/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ACE 3137/4885ACE2 3162/4885L3MBTL1 771/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | ACE 2924/4885ACE2 3115/4885L3MBTL1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.